Abstract: This article reviews possible use of ¹⁸F-labeled radiopharmaceuticals (excluding FDG) in oncology with positron emission tomography. The characteristics of various ¹⁸F-labeled compounds are proteins and peptides, those that bind to receptors, agents to assess hypoxia, and agents to evaluate gene therapy. Furthermore, different ¹⁸F-labeled tissue specific agents are indicated for the detection and monitoring of various malignancies.